View as an RSS Feed
Biotech Is Not A Popping Bubble: Buy The Dip While You Can
- Biotechnology indices were overbought and needed a correction.
- Short-term prices are particularly sensitive to sentiment.
- The biotech industry is not overvalued; its growth and profitability warrants sustained premium valuations.
- The correction should be over soon and you should buy the dip while you can.
It's Time To Reconsider Your Portfolio Strategy
Editors' Pick • Jul. 18, 2013 • 64 Comments